This study aimed to determine the ability of aqueous extracts of Terminalia arjuna bark extract to support left ventricular ejection fraction in a diverse population.

Keeping cardiovascular health in good shape is important for everyone, especially the elderly. During intense physical activity, the vast majority of aging individuals with or without heart failure increased sympathetic influences, which led to higher oxygen demand. Also, the prevalence of cardiovascular disease nearly doubled from 1990 to 2022.

According to studies, LVEF decreases by 1% every ten years of biological age. Reduction in LVEF may negatively impact cardiovascular health and increase fatigue and exertion during physical activity. Therefore, exercise, a healthy diet, and traditional botanicals with heart health benefits, such as the bark of Arjuna (Terminalia arjuna), are recommended to support optimal cardiovascular health.

Many marketed heart health products contain ingredients that may be beneficial to the heart. Some examples include omega-3 fatty acids, L-arginine, L-citrulline, astaxanthin, grape seed extract, hawthorn extract, zinc, copper, and magnesium.

These ingredients have been shown to support cardiac function through various pathways, including increasing nitric oxide production, enhancing myocardial contractility, alleviating arterial stiffness, improving endothelial function, providing antioxidant support, and modulating serum lipid levels and blood pressure.

Several clinical studies have demonstrated that TA bark can improve cardiac health, and the results have generally been positive. This preliminary evidence of TA’s cardiovascular health benefits led E-OJ-01 to develop an E-OJ-01 supplement to support adult cardiac health. However, participants in these studies were often ailing and were being treated for a clinical condition.

A previous study found that supplementing young exercising athletes with TA bark extract increased LVEF, decreased fatigue, and decreased exertion during treadmill tests.


The study employed 72 healthy adults aged 30 to 70 years (n=72) to measure the effect of 400 mg of E-OJ-01 per day administered for eight weeks on myocardial pumping capacity, primarily left ventricular ejection fraction (LVEF).

A secondary endpoint was an improvement in the diastolic filling ratio, the rate pressure product, and the fatigue severity scale. The experts also investigated blood lipid levels and levels of gamma-glutamine transaminase (GGT).

As part of the safety evaluation, adverse events, vital signs (heart rate, blood pressure, and body temperature), liver function (serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT)) and kidney function (serum creatinine) were monitored.

Results of the Study

From baseline, E-OJ-01 increased the LVEF by 6.28% compared to 0.24% in the placebo group and reduced fatigue, RPP, and GGT levels. No adverse events were observed as a result of the intervention.

Hence, according to the study, E-OJ-01 increased LVEF and reduced fatigue in a diverse, healthy population, improving cardiac pumping capacity.

Written by